Harnessing Immune Rejuvenation: Advances in Overcoming T Cell Senescence and Exhaustion in Cancer Immunotherapy
Aging Cell · 2025-05 · 24 (5)
DOI: 10.1111/acel.70055 ↗At a glance
Übersichtsarbeit in Aging Cell, published online on 2025-04-03. Written by Tesfahun Dessale Admasu and 1 co-authors. Institution: Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA. Major MEDLINE topics: Neoplasms, Immunotherapy, Cellular Senescence, T-Lymphocytes. Cited 29 times so far (Crossref); 203 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Immunotherapy has transformed the landscape of cancer treatment, with T cell‐based strategies at the forefront of this revolution. However, the durability of these responses is frequently undermined by two intertwined phenomena: T cell exhaustion and senescence. While exhaustion is driven by chronic antigen exposure in the immunosuppressive tumor microenvironment, leading to a reversible state of diminished functionality, senescence reflects a more permanent, age‐ or stress‐induced arrest in cellular proliferation and effector capacity. Together, these processes represent formidable barriers to sustained anti‐tumor immunity. In this review, we dissect the molecular underpinnings of T cell exhaustion and senescence, revealing how these dysfunctions synergistically contribute to immune evasion and resistance across a range of solid tumors. We explore cutting‐edge therapeutic approaches aimed at rewiring the exhausted and senescent T cell phenotypes. These include advances in immune checkpoint blockade, the engineering of “armored” CAR‐T cells, senolytic therapies that selectively eliminate senescent cells, and novel interventions that reinvigorate the immune system's capacity for tumor eradication. By spotlighting emerging strategies that target both exhaustion and senescence, we provide a forward‐looking perspective on the potential to harness immune rejuvenation. This comprehensive review outlines the next frontier in cancer immunotherapy: unlocking durable responses by overcoming the immune system's intrinsic aging and exhaustion, ultimately paving the way for transformative therapeutic breakthroughs.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Kairos Pharma, Los Angeles, California, USA.
ORCID profiles: Tesfahun Dessale Admasu
Cite
APA
Admasu, T. D., & Yu, J. S. (2025). Harnessing Immune Rejuvenation: Advances in Overcoming T Cell Senescence and Exhaustion in Cancer Immunotherapy. Aging Cell, 24(5). https://doi.org/10.1111/acel.70055
Vancouver
Admasu TD, Yu JS. Harnessing Immune Rejuvenation: Advances in Overcoming T Cell Senescence and Exhaustion in Cancer Immunotherapy. Aging Cell. 2025;24(5). doi:10.1111/acel.70055
BibTeX
@article{Admasu2025,
author = {Admasu, Tesfahun Dessale and Yu, John S},
title = {Harnessing Immune Rejuvenation: Advances in Overcoming T Cell Senescence and Exhaustion in Cancer Immunotherapy},
journal = {Aging Cell},
year = {2025},
volume = {24},
number = {5},
doi = {10.1111/acel.70055}
}
EUVIMED